Company Monitoring Page for Gilead-Sciences

latest headlines for company on cafepharma

GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth
Fierce Pharma
Sat, 04/28/18 - 12:13 pm
Tags:
GSK, HIV, Biktarvy, Gilead Sciences, Triumeq, Tivicay
The hepatitis C duopoly
Axios
Fri, 04/27/18 - 10:26 pm
Tags:
AbbVie, hepatitis C, Gilead Sciences
Gilead Receives Positive Opinion From CHMP on Combination HIV Drug Biktarvy
CP Wire
Fri, 04/27/18 - 11:39 am
Tags:
Gilead Sciences, Biktarvy, HIV
Fri, 04/27/18 - 09:55 am
Tags:
Gilead Sciences, Biktarvy, HIV
U.S. court upholds dismissal of $200 million Merck verdict against Gilead
Reuters
Thu, 04/26/18 - 07:31 pm
Tags:
Merck, Gilead Sciences, patents, hepatitis C
A Busy Week for the Supreme Court in FCA Matters
FDA Law Blog
Mon, 04/23/18 - 09:41 am
Tags:
FDA, False Claims Act, Gilead Sciences
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis
CP Wire
Fri, 04/13/18 - 12:16 pm
Tags:
Gilead Sciences, NASH, selonsertib, GS-9674, GS-0976
Medicare sets outpatient rate for Yescarta reimbursement
Reuters
Fri, 04/6/18 - 10:06 am
Tags:
Medicare, Yescarta, reimbursement, Gilead Sciences
Which Big Pharma CEOs Least Deserved Their Big Pay Increases?
Motley Fool
Wed, 04/4/18 - 08:59 am
Tags:
Big Pharma, Pharma CEOs, executive pay, AbbVie, Bristol-Myers Squibb, Gilead Sciences, JNJ, Pfizer
Gilead: Did Biktarvy Kill The Sell Thesis?
Seeking Alpha
Tue, 03/27/18 - 09:54 am
Tags:
Gilead Sciences, Biktarvy, HIV, Kite Pharma
Revenue down? No worries for Gilead CEO Milligan as compensation swells to $15.4M
Endpoints
Mon, 03/26/18 - 10:01 pm
Tags:
Gilead Sciences, Pharma CEOs, John Milligan, executive pay
3 Blockbuster Drug Launches to Watch In 2018
Motley Fool
Mon, 03/26/18 - 10:45 am
Tags:
drug launches, Gilead Sciences, HIV, Biktarvy, Alnylam, Sanofi, Patisiran, Epidiolex, GW Pharma
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
Thu, 03/22/18 - 09:21 am
Tags:
drug launches, Hemlibra, Roche, Biktarvy, Gilead Sciences, Ozempic, Novo Nordisk, Erleada, JNJ, Shingrix, GSK, Patisiran, Alnylam, Sanofi, Epidiolex, GW Pharma, Aimovig, Amgen, Novartis, lanadelumab, Shire, Elagolix, AbbVie, Steglatro, Pfizer, Merck, Sublocade, Indivior
Gilead Sciences' $14 Billion-Per-Year Threat
Motley Fool
Sun, 03/18/18 - 11:26 am
Tags:
Gilead Sciences, GS-9620, GS-9722, HIV
Is Gilead Sciences Trying to Put Itself Out of Business?
Motley Fool
Wed, 03/14/18 - 09:31 pm
Tags:
Gilead Sciences, hepatitis C, HIV, GS-9620, PGT121
[video]How Pricing Can Be Vital to a Drugmaker's Profitability
Motley Fool
Mon, 03/12/18 - 09:39 am
Tags:
drug pricing, Gilead Sciences, AbbVie, hepatitis C
Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys
Endpoints
Tue, 03/6/18 - 09:38 am
Tags:
HIV, Gilead Sciences, R&D
Gilead Sciences' History Points to Future Success
Motley Fool
Thu, 03/1/18 - 11:49 pm
Tags:
Gilead Sciences, hepatitis C, NASH
What's beyond hepatitis C in the drug launch hit parade? Ibrance and Tecfidera, for two
Fierce Pharma
Mon, 02/26/18 - 11:30 am
Tags:
drug launches, hepatitis C, Ibrance, Tecfidera, Biogen, Pfizer, Gilead Sciences
Gilead Sciences: The Oncology Company?
Motley Fool
Mon, 02/26/18 - 10:27 am
Tags:
Gilead Sciences, oncology, Kite Pharma, Cell Design Labs, Sangamo Therapeutics

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.